PhaseBio’s Bentracimab Could Benefit From Growth In Brilinta Demand

 
• By Alaric DeArment
  
3-D Rendering Red Blood Cells
PhaseBio presented data at AHA on its Brilinta-reversing agent, bentracimab • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas